Expertise in
10
conditions

Dr. Paul Ritch

Oncology
Froedtert And The Medical College Of Wisconsin Froedtert Hospital
9200 W Wisconsin Ave, 
Milwaukee, WI 
Expertise in
10
conditions
Froedtert And The Medical College Of Wisconsin Froedtert Hospital
9200 W Wisconsin Ave, 
Milwaukee, WI 

Overview

Paul Ritch is an Oncologist in Milwaukee, Wisconsin. Dr. Ritch is highly rated in 10 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Ampullary Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Pancreatectomy.

His clinical research consists of co-authoring 33 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in WI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Froedtert and the Medical College of Wisconsin Froedtert Hospital
9200 W Wisconsin Ave, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug, Radiation, Other
Study Drugs: Targeted Chemotherapy before Surgery, Standard FOLFIRINOX Chemotherapy Prior to Surgery, Gemcitabine after Surgery, Targeted Chemotherapy after Surgery
Study Phase: Phase 2
A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
Enrollment Status: Completed
Publish Date: December 27, 2022
Intervention Type: Drug
Study Phase: Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

33 Total Publications

Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Journal: Surgery
Published: February 17, 2020
Similar Doctors
Expertise in
3
conditions
Dr. Robert Montgomery
Hematology | Oncology
Expertise in
3
conditions
Dr. Robert Montgomery
Hematology | Oncology

Childrens Hospital Of Wisconsin Inc

8915 W Connell Ave, 
Milwaukee, WI 
 (0.1 miles away)
414-257-2424
Languages Spoken:
English
See accepted insurances

Robert Montgomery is a Hematologist and an Oncologist in Milwaukee, Wisconsin. Dr. Montgomery is highly rated in 3 conditions, according to our data. His top areas of expertise are Von Willebrand Disease (VWD), Blood Clots, Hemophilia A, and Immune Thrombocytopenic Purpura (ITP).

Expertise in
33
conditions
Dr. John Charlson
Oncology
Expertise in
33
conditions
Dr. John Charlson
Oncology

Clinical Cancer Center-Froedtert Hospital

8800 W Doyne Ave, 
Milwaukee, WI 
 (0.1 miles away)
414-805-0505
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Charlson is an Oncologist in Milwaukee, Wisconsin. Dr. Charlson is highly rated in 33 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Undifferentiated Pleomorphic Sarcoma.

Parameswaran Hari
Expertise in
32
conditions
Dr. Parameswaran Hari
Oncology
Expertise in
32
conditions
Dr. Parameswaran Hari
Oncology

Froedtert And The Medical College Of Wisconsin Froedtert Hospital

9200 W Wisconsin Ave, 
Milwaukee, WI 
 (0.1 miles away)
414-805-3666
Languages Spoken:
English
See accepted insurances

Parameswaran Hari is an Oncologist in Milwaukee, Wisconsin. Dr. Hari is highly rated in 32 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Primary Amyloidosis, Bone Marrow Transplant, and Splenectomy.

Frequently Asked Questions about Dr. Paul Ritch

How do I make an appointment with Dr. Paul Ritch?

You can book an appointment with Dr. Paul Ritch by calling their office at 414-805-6800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul Ritch a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul Ritch is classified as an Elite expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul Ritch specialize in?

While Dr. Paul Ritch is a Oncology, they have specific expertise in Pancreatic Cancer, Familial Pancreatic Cancer, and Ampullary Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Paul Ritch participate in research or clinical trials?

Yes. Dr. Paul Ritch has published 33 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Paul Ritch's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul Ritch accept my insurance?

Dr. Paul Ritch accepts most major insurance plans, including Humana. We recommend calling the office directly at 414-805-6800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ritch's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile